| | Latest News | Catalent Expands UpTempoSM AAV Platform to Accelerate Development of Gene Therapies |
|
| Catalent expanded its UpTempoSM platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain for the development and manufacture of gene therapies, and the reduction of timelines to first-in-human clinical evaluation. |
|
| | Read More | Catalent Publishes 4th Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments |
|
| Five years ago, Catalent launched a formal Corporate Responsibility (CR) strategy to align with our “Patient First” culture and drive our commitment to operational excellence and quality. Catalent has now published its fourth Corporate Responsibility Report, summarizing the progress made in |
|
| fiscal 2022 against previously published targets and commitments. Learn more about our ongoing work and achievements in areas such as environmental sustainability, a responsible supply chain, and diversity & inclusion.
To learn more, read our press release or the full report. | Catalent Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities |
|
| Catalent announced the completion of a $2.2 million expansion of its clinical supply facility in Singapore, which has seen the site’s footprint increase to 31,000 square feet creating the space to install an additional 35 new freezers for ultra-low temperature (ULT) storage. Learn more about the increased ULT storage capacity and associated capabilities now available as this strategic APAC hub celebrates 25 years of clinical supply excellence. |
|
| | Read More | Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary |
|
| Mr. Ferraro will be responsible for managing Catalent’s global legal and compliance operations. Commenting on his appointment, Steven Fasman, Catalent’s Executive Vice President and Chief Administrative Officer said, “Joe has extensive experience as a chief legal officer at public companies, which will be important as Catalent continues to grow in the highly regulated environments in which it operates. The entire executive leadership and I look forward to working with Joe.” |
|
| | | | | Bio/Pharma Outsourcing Innovation - Communication is Key in Complex Tech Transfer | How does the tech transfer of complex products, such as mRNA vaccines, differ from that of legacy small-molecule products?
The relationship between pharmaceutical companies and the contract organizations that perform development and manufacturing services comes with the necessary process of transferring intellectual information, processes, and product from one organization to another. To gain more insight on the complexities of transfer of pharmaceutical technology between contractors and sponsors, Pharmaceutical Technology spoke with Catalent experts, Sara Schemel, Senior Process Engineer, Dona York, Principal Process Engineer, and Gauri Patki, Senior Process Engineer on how communication can be the key to excel at complex tech transfer projects. |
|
| | | Catalent Appoints Sridhar Krishnan to Lead Global Ops Excellence Strategy |
|
| Catalent, Inc. has appointed Sridhar Krishnan to the newly created position of Vice President, ”The Catalent Way”, where he will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence, enabling growth. He will also serve on the Executive Leadership Team, reporting directly to Catalent’s President and Chief Executive Officer, Alessandro Maselli. |
|
| | Read More | Incannex partners with Catalent to manufacture psilocybin |
|
| Incannex Healthcare has collaborated with CDMO Catalent for the development and manufacturing of a cGMP-grade psilocybin product for clinical trials and potential commercial use. It is designed for use in Incannex’s psilocybin-assisted psychotherapy drug development program for generalised anxiety disorder. |
|
| | Read More | SPECIAL FEATURE – Solubility & Bioavailability: Difficult Beasts to Tame |
|
| Catalent: Formulation Approach Puts Clients on a Path to First-in-Human Clinical Studies
This exclusive Drug Development & Delivery annual report highlights the services of outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes. William Wei Lim Chin, Ph.D., Manager, Global Scientific Affairs, Catalent, shares insights and best practices formulators dealing with solubility and bioavailability issues. | | Read More |
|
| | | Endpoints News Editor-in-Chief John Carroll sits down with Catalent’s President and Chief Executive Officer, Alessandro Maselli, to talk about the year ahead, offering their thoughts on what 2023 may hold in store for the biopharma industry. |
|
| Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs and Commercial Programs |
|
| Biologics
Accelerating Biologics Through the Clinic: A Seamless Development-to-Manufacture Approach | Copenhagen, Denmark | March 28, 2023 Join us for this in-person event where industry experts will focus on the key considerations for transitioning a molecule from clinical to commercial scale, beginning with cell line development and biomanufacturing, to formulation and filling and managing clinical trial supply. Register now
World Vaccine Congress Washington 2023 | April 3-6, 2023 | Washington, DC Visit booth 1117 to chat with our Cell and Gene Therapy experts and learn about Catalent’s integrated solutions for advanced therapeutics.
Cell & Gene Meeting on the Med | April 12-14, 2023 | Barcelona, Spain Schedule your meeting with our Cell and Gene Therapy team to hear about our integrated solutions and how we can support in bringing your next transformative therapy to market.
Webinar | Development of Orphan Biologics: Challenges and Opportunities | April 18, 2023 The development of therapies for rare diseases comes with distinct challenges such as patient recruitment, difficulties in setting meaningful clinical endpoints, and manufacturing and supply challenges. In this webinar, speakers will cover aspects of clinical trial design for orphan biologic products as well as key strategies for ensuring appropriate clinical trial supply throughout clinical development. Register now CASSS Bioassays 2023 | April 12-14, 2023 | Gaithersburg, Maryland Meet Catalent experts at booth 4 and learn about Catalent’s integrated solutions that can help better biologic and advanced treatments to patients, faster.
|
|
| Pharmaceuticals and Consumer Health
Targeted Protein Degradation Summit Europe | London, UK | March 28-30, 2023 Join Steven Winling, Scientific Advisor, Science & Technology, as he discusses Catalent’s tailored developability assessment for bifunctional protein degraders, which can help predict viable formulation and drug delivery strategies for lead drug candidates to reach their true potential. Schedule a meeting
in-cosmetics Global 2023 | Barcelona, Spain | March 28-30, 2023 Meet the Catalent Beauty team at Booth N61 to learn more about our capabilities for your beauty needs and how we can partner with you on your next project. Schedule a meeting
Road to IND: Accelerating Development & Manufacturing of Oral Small Molecule | San Deigo | April 4, 2023 Join this event featuring speakers from Catalent, JLABS and UC San Diego focusing on several key considerations for developing the best small-molecule drug product for patients.
Workshop: De-risking small molecule early drug development with expert technology selection| Barcelona, Spain | April 27, 2023 Join us in Barcelona as Catalent experts provide insight into how to classify new therapeutic drug candidates for issues relating to oral product development, anticipate and address challenges early, and plan for success in preclinical and early-stage clinical studies. Book your 1 on 1 free meeting slot now! Schedule a meeting
2023 CMAC Annual Meeting | April 7-9, 2023 | Suzhou, China Meet our clinical supply experts in booth A55 to learn how Catalent’s dual Shanghai facilities and global network can help overcome your clinical supply challenges, in China and beyond. On April 7, hear Leo Xu, Project Management Director, Catalent Clinical Supply at Catalent present ‘Proactive Strategies to Evaluate & Mitigate Clinical Supply Risk.’
Nicholas Hall’s 33rd CHC European Conference | London, UK | April 20-21, 2023 Visit our booth and meet Catalent’s experts to learn more about our development and manufacturing capabilities for consumer health products. Schedule a meeting
|
|
|
|
Biologics Whitepaper: “ Integrated Solutions for Advanced Therapies” Drug developers face mounting challenges linked to rapid increases in demand for the complex modalities while also accounting for the need to drive process efficiencies at scale. Working with the right partner, that offers integrated services, can help ease the increasingly common problems with scale, access to high-demand raw material, viral vector production, and quality requirements. Read this whitepaper to learn more.
Video: “ Catalent Cell & Gene Therapies – Changing the Healthcare Landscape” Catalent Cell & Gene Therapy experts spoke with American Pharmaceutical Review to discuss how cell and gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.
Article: “Biopharma 4.0 – Spearheading Digital Transformation in the Biopharmaceutical Industry” For Contract Development and Manufacturing Organizations (CDMOs), transitioning to Biopharma 4.0 is crucial – the data and expertise amassed by these manufacturers represent an integral asset for their customers working to innovate in an increasingly competitive and fast-paced market. In this article, experts discuss insights on how to embrace changes for better outcomes for the biopharma manufacturing industry.
Webinar: “Antibody-drug conjugates (ADC)’s are Back Stronger Than Ever: How, Why & What’s Next” In this on-demand presentation, Mike Riley, President, Catalent Biologics, discusses the latest trends in ADC discovery and development, with a focus on how next generation pipelines are being shaped by payload and linker chemistry innovations, including those from Catalent’s award-winning SMARTag® ADC platform.
White Paper: “ Leveraging Novel Analytical Approaches for Advanced Therapies” Catalent has developed a relative potency bioassay using quantitative polymerase chain reaction (qPCR) to assess relative transcription activity in cells treated with ligands or transgenic vectors. In this white paper, read about how the assay platform can be used to qualify a repeatable, accurate, linear, and specific bioassay for assessing relative potency for cell & gene therapies, mRNA- and other nucleic acid-based therapies. |
|
| | | | | | | | In this 360° virtual tour of our Anagni, Italy, site, explore the world-class late-stage and commercial manufacturing for vial fill/finish and secondary packaging of biologics and sterile products. |
|
| Pharmaceuticals and Consumer Health
| | In this 360° virtual tour, explore Catalent’s Kakegawa, Japan facility which offers Softgel development and manufacturing capabilities for the Pharmaceutical and Consumer Health industries. |
|
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are hiring across sites in North America, Latin America, Europe and Asia Pacific.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every molecule has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.
© 2023, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
|
|
|
|
|
